A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer

Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). How...

Source: BMC Cancer - June 7, 2019 Category: Cancer & Oncology Authors: Akihito Tsunoda, Kei Morikawa, Takeo Inoue, Teruomi Miyazawa, Masahiro Hoshikawa, Masayuki Takagi and Masamichi Mineshita Tags: Research article Source Type: research